This action might not be possible to undo. Are you sure you want to continue?
Reference for Business
Company History Index
Reference for Business » Company History Index » Drugs
Abbott Laboratories - Company Profile, Information, Business Description, History, Background Information on Abbott Laboratories
100 Abbott Park Road Abbott Park, Illinois 60064-6400 U.S.A.
Abbott's vision is to be the world's premier health care company. Simply put, we want to be the best--the best employer, the best health care supplier, the best business partner, the best investment and the best neighbor. While Abbott is broadly diversified, all of its thousands of products and people are dedicated to a common mission: to improve lives by providing cost-effective health care products and services.
History of Abbott Laboratories
Abbott Laboratories is one of the oldest and most successful pharmaceutical companies in the United States. While about 30 percent of annual revenues come from the sale of pharmaceuticals--including Abbott's flagship drug, the antibiotic Biaxin--the company has a higher profile in the area of nutritionals, where its products include leading infant formula brands Similac and Isomil and a leading adult nutritional brand, Ensure. Abbott is also a top manufacturer of medical diagnostic equipment, with an emphasis on blood analyzers and the detection and monitoring of infections and diseases. The firm's hospital products unit produces electronic and injectable drug-delivery systems, intravenous solutions and supplies, anesthetics,
Abbott's death that year. Abbott. Abbott began to advertise his products to other doctors in 1891. however. A more dynamic character than any since Dr. American pharmaceutical companies such as Abbott were much less dependent on Germany's companies. Dr. as several important drugs. tranquilizers. and barbital. DeWitt Clough was named president of the company in 1933. Alkaloid pills soon became available in Chicago.and products used in critical care settings. diabetes. So successful was his business that he eventually sold shares to other doctors and incorporated his operation in 1900 as the Abbott Alkaloidal Company. By this time. Clough is best remembered for the inauguration of the company magazine. Inventors Hall of Fame for this discovery). During World War I. North Carolina. Abbott expanded outside the United States for the first time with the establishment of an affiliate in Montreal. strychnine. As did other physicians of the time. Abbott's company was essential to the medical community. Abbott's annual research and development budget exceeds $1 billion. quinine. After the war. ending a period of somewhat stale communal leadership. Abbott once again played an important role in battlefield and hospital healthcare. which had been developed by Abbott scientists Ernest Volwiler and Donalee Tabern (who in 1986 were named to the U. and codeine--all of which were liquid alkaloid extracts--for his patients. with areas of emphasis including AIDS/antivirals. Even after Dr. and vitamins. a substitute for the German novocaine. and he decided to manufacture his own. Two years later. manufactured exclusively by German companies. . it was already a worthy competitor on its own. Early Decades Abbott Laboratories has its origin in the late 19th century in a small pharmaceutical operation run from the kitchen of a Chicago physician named Wallace Calvin Abbott. In 1921. Abbott was dissatisfied with their quality. Ten years later.S. Abbott continued to concentrate on the research and development of new drugs. a replacement for veneral. urology. Because they existed only in a liquid form. particularly the IG Farben--a conglomeration of the world's most advanced drug manufacturers. anti-infectives. After the war. Canada. Abbott commonly prescribed morphine. What's New? The publication had such a positive impact on worker morale and public opinion that several of Abbott's competitors started similar publications. The company went public in 1929 with a listing on the Chicago Stock Exchange. mitigating their effectiveness as treatments. Dr. the company continued to invest heavily in new product development and aggressive marketing campaigns. the company established a laboratory in Rocky Mount. including sedatives. Abbott developed procaine. Abbott. had little to gain from this information. neuroscience. annual sales had grown to $200. Abbott heard that a Belgian surgeon had developed alkaloids in solid form. were no longer available in the United States. much of the IG Farben's research was turned over to American manufacturers. By 1905. these drugs were prone to spoilage over time. the company changed its name to Abbott Laboratories. which developed a number of new drugs. During World War II.000. pediatric pharmaceuticals. Dr. oncology. In 1888. and vascular medicine. In 1936 Abbott began its long-term association with anesthetics when it introduced sodium pentothal. but Dr.
institutional market. it was marketed to diabetics.After the departure of DeWitt Clough in 1945. as Americans became more health and diet conscious. New drugs had greater profit margins but were subject to government approval procedures that kept companies waiting for several years before they could market their discoveries. including Pream nondairy creamer. He advocated a reduction in Abbott's emphasis on pharmaceuticals by diversifying into other fields. formed the basis for Abbott's market-leading infant and adult nutritionals business.E. Faultless golf balls. Abbott introduced an array of consumer products. Sales of the drug increased dramatically when it was found to be an effective treatment for Legionnaire's disease. Abbott was able to cross-subsidize failing operations until they could be rehabilitated. the cyclamate sugar substitute. Abbott shifted its attention to the development of antibiotics. Abbott's management decided to maintain the strategies that were in place. however. introduced under the brand names Erythrocin and E. In 1964 Abbott completed the first major acquisition in company history when it purchased Columbus. Glad Hands rubber gloves. it was increasingly used as a sugar substitute in a wide variety of foods. Ledder's policy of diversification laid the groundwork for more flexible corporate strategies. Unable to increase profits without substantial risk. in charge of the division.S. The chemical. The increasing popularity of cyclamates as an ingredient in diet foods. Then. Ohio-based M & R Dietetic Laboratories. The company's hospital products competed in a limited. in 1967. and none was projected at any time in the immediate future. a highly experienced and able manager he had hired away from Revlon. on the other hand. could be used as an artificial sweetener. The FDA's research was widely criticized as 'fragmentary' and 'fatally flawed. but in the 1960s. constituted a significant portion of Abbott's prescription drug sales for several decades--even after the expiration of its 17-year patent. Edward J. Abbott soon realized new obstacles to its growth. No longer exposed exclusively within the pharmaceuticals market. involved more expensive marketing and generated less profit than pharmaceuticals. a cyclamate. led the Food and Drug Administration (FDA) to conduct an investigation of possible side effects from their overuse. from 1950. Abbott stumbled onto a lucrative new product when one of its researchers accidentally discovered that a chemical with which he had been working had a sweet taste. in 1952. The market collapsed in August 1970 when the FDA banned . Ledder placed Melvin Birnbaum. Late 1960s and Early 1970s: Diversification and Crises By the mid-1960s. Ledder was named president of the company. In an effort to ensure the success of Abbott's consumer product line. and Sucaryl. Consumer products. Cyclamate sales had grown so dramatically that by 1969 they accounted for one-third of Abbott's consumer product revenues--or about $50 million. The company developed the antibiotic erythromycin. Abbott had gone several years without a major breakthrough in research.' but it was nonetheless used as evidence that cyclamates were carcinogenic. Despite this flexibility. Initially. In the years that followed. M & R was the manufacturer of Similac baby formula and over the succeeding decades. which. as the company's Ross Products Division.
Nutritionals. expansion into foreign markets. His efforts as a vice-president in the hospital products division at Abbott resulted in a revenue increase of 139 percent for that division between 1974 and 1979. but the company was unable to regain its leadership of the intravenous market. it was discovered. conditions were obviously ripe for the expression of talent by a new manager.5 percent by 1979. vitamin therapy. reduced costs. and greater involvement in hospital nutritionals and diagnostic testing equipment. Meantime.4 million bottles of intravenous solution. a veteran of the chemical industry. as many as 65 percent of all . a mild tranquilizer. an anticonvulsant. In the 1980s. Litigation resulted in the company eventually pleading no contest to a charge of conspiracy and paying a $1. Abbott was forced to recall 3. in 1977 Abbott entered into a joint venture with Takeda Chemical Industries. Schoellhorn was later promoted to president and chief operating officer of the company. Abbott. Abbott moved quickly to replace its Gilsonite seals with synthetic rubber. Late 1970s Through 1980s: Emphasizing R & D. The bottles were sealed with a varnished paper called Gilsonite. Robert Schoellhorn. Although the company continued to petition the FDA. but was unable to reverse the decision. which overnight had suffered the loss of one of its most profitable operations. Abbott developed a comprehensive nutritional therapy program to speed the recovery of hospital patients and thereby reduce medical care costs. The company also introduced three new drugs in 1979: Depakene. The Center for Disease Control linked the contaminated solutions to at least 434 infections and 49 deaths. Ltd. Utilizing its knowledge of intravenous solution production. Abbott's share price began to fall. for the codevelopment and comarketing of pharmaceuticals. and Abbokinase. He correctly predicted that the next most profitable trend in healthcare would be toward cost-effective analysis and treatment.domestic sales of cyclamates. Although Edward Ledder was recognized for the success of his diversification program (and largely excused for his inability to prevent either the cyclamate ban or the intravenous solution crisis). protested the ban.5 percent and an earnings growth rate of 16. With sales down from $17. Diagnostic Equipment The crises of the early 1970s left the company's upper echelon of management weakened and vulnerable to criticism. which. a treatment for blood clots in the lungs.000 fine. of Japan called TAP Pharmaceuticals Inc. Less than a year after cyclamates were banned. was just such a manager. Tranxene. All three products were the direct result of the company's increased investment in research and development in the mid-1970s. subsequent studies confirmed that metabolization of cyclamates can lead to chromosome breakage and bladder cancer.9 million to $3 million. The contamination was discovered only when healthcare workers noticed and then investigated the high incidence of infection in patients who had been administered Abbott's intravenous solutions. This expansion was attributed by financial analysts to the company's increased productivity. and infant formula. harbored bacteria. Abbott Laboratories registered an annual sales growth rate of 15.
and Eli Lilly). These devices were increasingly used to detect legal and illegal substances in the bloodstream. The introduction of Murine eye-care products and Selsun Blue dandruff shampoo served to expand the domestic consumer product line and promised to provide earning stability in the event of a downturn in any of the company's other markets. Abbott accused Schoellhorn of misappropriation of company assets and 'fraudulent conduct. Burnham. especially blood analyzers. Abbott in 1987 received FDA approval for a new drug called Hytrin for the treatment of hypertension. The company's 'Vision' blood analyzer fit on a desktop and performed 90 percent of typical blood tests within eight minutes. Abbott hired two top executives away from Texas Instruments to head the division. Hytrin was approved in 1993 for the treatment of noncancerous enlarged prostate.3 billion per year) constituted nearly half of Abbott's annual sales. the company plowed funds into research and development. developing the first diagnostic tests for Acquired Immune Deficiency Syndrome (AIDS). in the pharmaceuticals arena.' adding that the former CEO exercised stock options worth $9. Another advantage of adult nutritional products was that they had a place in the growing home care market. often led to conflict. Schoellhorn continued to support Ledder's original diversification policy. Abbott led the trend.hospital patients suffered from some form of malnutrition. Abbott had similar success marketing its lines of diagnostic equipment. Instead. Schuler (1989)--quit. who advanced to chairperson and chief executive officer in 1979. Abbott's board of directors unseated Schoellhorn. R & D expenditures neared $1 billion. Electronic testing devices developed by Abbott proved more accurate than manual procedures. R & D outlays rose from 5. Vincent (1981). and medical diagnostic products (at $2. and the company had more than 75 foreign subsidiaries and manufacturing facilities in more than 30 countries. In order to strengthen the technical end of its diagnostic equipment research. Foreign operations also remained extremely important to Abbott. continued to emphasize investment in pharmaceutical research and development in the 1980s. profits doubled. The leader's aggressive management style. and the pharmaceutical company rose to 90th from 197th on Fortune's list of the world's top 500 companies. 1990s and Beyond: New Drug Introductions and Acquisitions Unlike many of its competitors (including Merck. in 1985. Seven new drugs introduced in 1982 accounted for 17 percent of sales in 1985. and hepatitis. In December 1989. Robert Schoellhorn. and Jack W. Schoellhorn was also credited with promoting Abbott's emphasis on diagnostic equipment.3 million within days of his release. Meanwhile. Schoellhorn was succeeded by Vice-Chairman Duane L. .2 percent of sales in 1982 to more than 10 percent of sales by 1994--by the latter year. who in turn sued the company for his job. By the end of the 1980s. SmithKline Beecham. sales of blood analysis devices represented a billion-dollar business. so Abbott was highly successful in marketing their program. Abbott did not acquire a drug distribution manager in the early 1990s. three presidents-James L. Schoellhorn was widely praised as the driving force behind Abbott's phenomenal growth during the 1980s--sales nearly tripled. however. Over the course of the 1980s. Kirk Raab (1985).
In 1997 Abbott spent about $200 million for certain intravenous product lines of Sanofi Pharmaceuticals. however.3 billion by 1998). Abbott suffered a potential setback when Takeda Chemical did not renew a ten-year contract that gave Abbott the right of first refusal to distribute Takeda's new drugs in the United States via the TAP venture. Takeda had decided to set up its own sales and marketing organization in the United States. The Federal Trade Commission (FTC). In 1996 FDA clearance was granted for Norvir. a Waltham. White. During 1999. Shrugging off the conservative management of the early 1990s. a protease inhibitor for the treatment of HIV and AIDS. an ulcer treatment (sales of Prevacid reached $1. TAP. a prostate-cancer drug. Abbott's appetite for growth increased exponentially with the announcement in June of a deal to acquire ALZA Corporation for $7.3 billion in stock. By this time TAP was generating annual sales in excess of $2 billion. Abbott moved aggressively in the second half of the decade to expand via acquisition and thereby stave off being acquired itself. for $234 million. Inc. the U. Abbott acquired Murex Technologies Corporation. single-dose syringes. Despite these R & D successes.A. Miles D. who had been a senior vice-president in charge of the diagnostics division. Inc. During the leadership transition period in 1998. White was named chairman as well. and when the two sides were unable to reach an agreement with the FTC. ALZA was a leading producer of advanced drug-delivery systems and had a solid pipeline of new pharmaceuticals under development. received FDA approval for Prevacid. clorithromycin was useful in the treatment of common upper respiratory ailments such as the flu as well as other types of infections. By 1997 Abbott had doubled its sales and earnings since Burnham had taken over from the ousted Schoellhorn. The following year. This was the company's first major deal since the 1964 acquisition of M & R Dietetic Laboratories.. New product introductions continued in the middle years of the decade.That year marked the company's 23rd consecutive earnings lift and helped Abbott's stock hold its value better than most competitors in the uncertain healthcare environment of the early 1990s. a maker of diagnostics products. an injectable drug-delivery system based on preloaded. Also in 1997. Massachusetts-based maker of blood-testing devices for diabetics. Later in 1999. primarily from the marketing of Prevacid and Lupron. an antibiotic developed as a successor to Abbott's erythromycin. In 1996 Abbott bolstered its diagnostics division through the $867 million purchase of MediSense.. Abbott's earnings were failing to increase at the high-doubledigit rate that they had in the 1980s. and the company was beginning to face the risk of being gobbled up by a larger rival in the rapidly consolidating healthcare industry of the 1990s.S. Marketed in the United States under the name Biaxin. Among key developments in the early 1990s was the introduction in 1991 of clorithromycin. they called off the merger in December. Another possible factor in the collapse of the deal was the decline in Abbott's stock price . the joint venture with Takeda Chemical. unit of France's Sanofi S. an inhalation anesthetic that soon gained popularity because of its wide range of uses. Included in this deal was Carpujet. At the beginning of that year. took over as CEO. It quickly became Abbott's flagship pharmaceutical--eventually achieving $1 billion in annual sales--remaining so into the early 21st century. In 1994 Abbott introduced sevoflurane. In early 1998 Burnham announced that he would retire in 1999. raised antitrust concerns about the merger.
Abbott Laboratories Argentina. CMM Transportation. Alcyon Analyzer S. Solartek Products. for about $600 million in stock... Abbott Health Products. Inc. The FDA also cited poor manufacturing controls as the reason for its halting the sales of Abbott's clot-dissolving agent Abbokinase in early 1999. Abbott Fermentation Products de Puerto Rico. Corporate Alliance. S. Abbott Laboratories (Puerto Rico) Incorporated. S.. Inc. Abbott. unit of German chemical giant BASF AG for $6.H.. Incorporated. S..S. (Germany). MediSense France SARL. Abbott Laboratories Limited (Canada). Ltd. a $150 million thyroid drug.A. Abbott OY (Finland). Abbott Laboratories de Colombia. Oximetrix de Puerto Rico. Abbott International Ltd. Inc. Abbott Diagnostics G.A. Murex Diagnostica. Spol. Inc.V. because it had fewer side effects. Inc. with the market withdrawal and payment of the fine being the outcome of this process. Abbott was now for the first time in decades a pure healthcare firm. MediSense Australia Pty. Inc. Inc. TAP Finance Inc. Principal Subsidiaries: Abbott Chemicals Plant. (Germany). a secondgeneration AIDS medication developed by Abbott. Abbott Laboratories A/S (Denmark).A.. (Barbados). Inc. Kaletra had the potential to overtake the top AIDS drug.. North Shore Properties. Abbott Laboratories Inc..A. an obesity drug with annual sales of about $400 million.b. (Austria)..S. Abbott. Swan-Myers. Abbott Laboratories Residential Development Fund.. Abbott managed to complete two smaller acquisitions in 1999. (Czech Republic).. International Murex Technologies Corporation (Canada). (Belgium). It also appeared that patients did not develop resistance to Kaletra over time. The acquisition would also boost Abbott's pharmaceutical R & D budget to nearly $1 billion.r. market and to pay a $100 million civil penalty to the U.. In January 2000 Abbott sold its agricultural products business to Sumitomo Chemical Co. Abbott Laboratories Pacific Ltd.. S. Abbott Universal Ltd.. Limited (Australia). Abbott Laboratories Services Corp. Murex Diagnostics (France) S.. Murex Diagnostics. Abbott Laboratorios del Ecuador. of Puerto Rico. Abbott in April of that year began marketing Biaxin XL.. Abbott's aim was to bolster its product pipeline.A. Pfizer Inc..b.H. (Czech Republic). In the meantime. Since 1993 the FDA had been issuing warnings to Abbott regarding quality control deficiencies at its test kit plants.. as happened with most other AIDS drugs. Perclose.m.. government. Inc.. Abbott Laboratories International Co. Abbott Laboratories de Chile Limitada (Chile). (Brazil). Then in December 2000 Abbott launched another attempt at a major acquisition when it reached an agreement to acquire the Knoll Pharmaceutical Co. IMTC Technologies. Inc. Inc. Abbott Home Infusion Services of New York. Knoll's existing products included Meridia. an experimental rheumatoid arthritis treatment. The FDA in September 2000 granted expedited approval to Kaletra. Abbott Trading Company. Inc. Abbott Australasia Pty. Tobal Products Incorporated.o.. Inc.. Sorenson Research Co. Abbott Gesellschaft m. Ltd.A. (El Salvador). Inc.A. Abbott G.m. including Viracept. AC Merger Sub Inc.. Abbott Laboratorios do Brasil Ltda..H.'s Viracept.o. Abbott Laboratories s. Inc. Murex Diagnostica GmbH (Germany). Abbott International Ltd. for five anesthesia products. a maker of sutures used to close arteries during angioplasty procedures.following the company's agreement in November to pull 125 types of medical-diagnostic test kits off the U... and Knoll had at least one potential blockbuster in a drug called D2E7. Murex Diagnostics A/S (Denmark). It acquired Perclose.9 billion in cash. Once again. s.. Abbott also paid $217 million in cash to Glaxo Wellcome Inc. and Synthroid.... Inc. Abbott France S... Abbott .. Abbott Hospitals Limited (Bahamas). S.b. Murex Diagnostics International.A.r. a new once-daily formulation of its flagship Biaxin antibiotic. de C. Inc.
Abbott Laboratories. Abbott S. (Greece).V. Inc. (Switzerland). IMTC Holdings B.). Limited. Ledder begins a diversification into consumer products. (Venezuela). Novartis AG.B.A. Murex Diagnostici S. (Netherlands).) Limited. IMTC Holdings (UK) Limited..V. Abbott Laboratories. MediSense Europe B. Abbott Laboratories Taiwan Limited. de C.p. .V.A. Abbott Laboratories South Africa (Pty. Abbott Laboratories B. Abbott Laboratories (N. Abbott Finance Company S. (Peru). Abbott Laboratorios S..A. Abbott Laboratories Limited (Hong Kong). Limitada (Portugal).R. (Netherlands). Abbott Ireland Ltd.42%). z. Erythrocin. Bhd.).A.A. 1967: New president Edward J. (Panama).). Abbott Laboratories Sp. (Guatemala). Roche Holding Ltd. Wallace Calvin Abbott begins manufacturing alkaloid pills. 1900: Abbott incorporates his firm as Abbott Alkaloidal Company..). S. Abbott A. Abbott Overseas. S. (Italy).V. Hospital Products. MediSense Netherlands.K.A.A.V. Johnson & Johnson.A. S.V. (Netherlands).V. Medicamentos M & R. Chronology Key Dates: 1888: Dr.G.K. Abbott Scandinavia A.A. (Netherlands). Bristol-Myers Squibb Company.o. maker of Similac baby formula. (Spain).. (Venezuela). Abbott Laboratories de Mexico. Dainabot Co. (Netherlands). (Spain). Abbott Laboratories Trustee Company Limited (U. (Panama). Abbott Cientifica.V. Abbott Laboratories Uruguay Limitada. Ross Products.A. Abbott Laboratuarlari Ithalat Ihracat Ve Tecaret Limited Sirketi (Turkey). Abbott Laboratories (Malaysia) Sdn. (Switzerland).V. Abbott Laboratories. Abbott Laboratorios. Abbott Laboratories S. Eli Lilly and Company. Edisco B. (Switzerland). 1952: Company launches a new antibiotic. (Lebanon).A. Abbott Laboratories Limited (Thailand). Abbott Laboratories (Hungary) Ltd. (U. Abbott Laboratories Limited (U. Abbott Holdings B. American Home Products Corporation. Abbott Laboratories (India) Ltd. (Netherlands). S. Abbott Middle East S. including Sucaryl.K. Bayer AG. Abbott Japan K. Abbott Laboratorios. Abbott International. (51%). (Italy). (Japan.A.K. P. MediSense UK Ltd. Abbott Norge A S (Norway).. S. (Poland).A. Ireland. a cyclamate sugar substitute. Principal Divisions: Pharmaceutical Products. AstraZeneca PLC. C. (Netherlands). Abbott B. Abbott Indonesia (97%). (Netherlands).K. (Japan). Specialty Products. 73%).A.V.. Abbott Laboratories (Singapore) Private Limited. Pfizer Inc. Ltd. MediSense Britain..).V. 1964: Abbott acquires M & R Dietetic Laboratories. Specialist Diagnostica Limited (U. Schering-Plough Corporation. Murex Biotech Limited (U. C. Diagnostics.K.o. Abbott Finance B.. Aventis.) Limited (New Zealand).. GlaxoSmithKline plc. Abbott Laboratories (Philippines). Abbott Korea Limited. 1936: Company introduces the anesthetic sodium pentothal. (Netherlands).Laboratories (Hellas) S. B. Abind Healthcare Private Limited (India). (Sweden).Z.p. S. Abbott Laboratories (Mozambique) Limitada. Ltd. Abbott (UK) Holdings Limited.L.).. 1915: Company changes its name to Abbott Laboratories. 1929: Abbott goes public with a listing on the Chicago Stock Exchange.K. IMTC Finance B.T.A. Abbott Laboratories. Abbott Investments Limited (U. Abbott Laboratories (Pakistan) Limited (83. Murex Diagnostics Benelux B. Principal Competitors: Merck & Co.
1987: Abbott's Hytrin is approved by the FDA for the treatment of hypertension. an antibiotic.. 325413 In-Vitro Diagnostic Substance Manufacturing. A3. 1999. 7. October 11.3 billion but the deal later collapses. p. 'Abbott's White Wins CEO Job. November 28.9 Billion. pp. 1988.' Modern Healthcare. 1999.' Wall Street Journal.Bleiberg. 34+. 1971: Abbott is forced to recall 3. 1985: Abbott develops the first diagnostic test for AIDS. 28. Amy. June 18. 'Abbott Laboratories and Alza Call Off Their Deal. Inc.' Business Week.' but Oversight Is Faulted. Thomas M. August 29.' Business Week. Ltd. pp. 'Aloof But Not Asleep. A3. 88+. 1994. Sarah . pp.' Forbes. Heal Thyself.'Bob Schoellhorn Is Refusing to Go Quietly. 1984. pp. B10.Barrett. 1990. of Japan called TAP Pharmaceuticals Inc. 1986.Burton. Inc. is acquired. p. 334516 Analytical Laboratory Instrument Manufacturing. 1970: FDA bans the sale of cyclamates. Kim.------. is introduced. p. 2000. 56+. December 15. p. Robert M.------. October 17.' Business Week. 43-44. Engineering.Carter. suture maker Perclose.' Financial World. 138+. 222+. September 16. 2000: FDA approves the AIDS drug Kaletra. June 1.. 1977: Company forms joint venture with Takeda Chemical Industries. December 17. A3. 'Abbott Laboratories Betting Its Future on the Development of New Products. 'Drugmaker. Abbott agrees to pay a $100 million fine relating to quality control problems at its medical test kit plants.' Wall Street Journal.' Forbes. pp.Berss. November 7.------. Marcia. 'Federal Judge Clears Abbott in Formula Case: Bid Process for Infant Food Is Called `Questionable. 1994. 311514 Dry.' Wall Street Journal. A12.' Wall Street Journal. p. A3. unit of BASF AG for $6.'Baby Bottle Battle. 'Abbott to Pay $100 Million in Fine to United States. 1999: Abbott agrees to acquire ALZA Corporation for $7. October 9. 1999. and Life Sciences Further Reference 'Abbott: Profiting from Products That Cut Costs. pp. 1989. 541710 Research and Development in the Physical. Additional Details Public Company Incorporated: 1900 as Abbott Alkaloidal Company Employees: 60. 1991: Clorithromycin. March 26. 1996: Abbott acquires MediSense. and Evaporated Dairy Product Manufacturing. 'Abbott and Costello: The Ban on Cyclamates Is a Comedy--or Tragedy--of Errors.------. a maker of blood-testing devices for diabetics. pp. November 3.' Wall Street Journal.Klein.000 Sales: $13. Condensed. 'Abbott Laboratories: Room at the Top.Benoit. Abbott agrees to acquire the Knoll Pharmaceutical Co.' Barron's. 1978. and Richard A. 'Abbott Labs to Buy BASF Unit for $6.75 billion (2000) Stock Exchanges: New York Chicago Pacific Boston Cincinnati Philadelphia London Swiss Ticker Symbol: ABT NAIC: 325412 Pharmaceutical Preparation Manufacturing. Melcher.9 billion in cash.4 million bottles of intravenous solution. p. Ellen.. 1998.
June 13.-----. p. 2001.Kogan. B6.' Crain's Chicago Business. 4. 1963.Company Profile. June 22. 309 p. The Long White Line: The Story of Abbott Laboratories. September 4. Herman. September 21.A. U. Information. 1999.Merrion. March 12.' Wall Street Journal.' Crain's Chicago Business.' Crain's Chicago Business. 1991. p. New York: Random House. p. 1998.Somasundaram.' Crain's Chicago Business.' Wall Street Journal.. 'New CEO Poised to Rev Up Sleepy Abbott's Strategy. 'Infant-Formula Firms Rigged Bids. Business Description. A3.------. Arsenio. 1992.-----. Kevin G. March 2. Meera... History. 1. 1988.S. 3. Says.------. April 8. p. January 1.html#ixzz1sNPfAuqi . Drawing Lawsuit by Embattled Official. 'Restocked Product Pipeline Invigorating Abbott.' Crain's Chicago Business.' Wall Street Journal. 'Abbott's Biotech Biz Gets a Booster Shot: Picking Up Keys to State-of-the-Art Lab in BASF Deal. or add new information about this topic: Name: E-mail: Display email publicly Security Code: Comment: (50-4000 characters) Abbott Laboratories forum Copyright © 2012 Advameg. 1999. Read more: Abbott Laboratories . 'Abbott Tries Costly Growth Drug: M & A. p.' Crain's Chicago Business. User Contributions: Comment about this article. October 21. Jr. 4.referenceforbusiness. 1990. 'Nestlé Sours Baby Formula for Abbott.' Crain's Chicago Business. p. p. 4. ask questions. June 12. A3. 4.Miller. 1998. 3. Paul. 'Abbott's Prescription for Sluggish Drug Biz Pays Off. 'Abbott Labs Agrees to Purchase Alza.. February 1. 'Abbott Set to Stock Medicine Cabinet: Drug Giant Expected to Shop for Mid-Sized Rivals.' Crain's Chicago Business. James P.------. p. 1996. 2000. p. 'Abbott's Tough Rx: Buy or Risk Being Bought. 'Abbott Ousts Schoellhorn As Chairman.Salwan.Oloroso. p. Background Information on Abbott Laboratories http://www. Inc.com/history2/32/Abbott-Laboratories.
This action might not be possible to undo. Are you sure you want to continue?
We've moved you to where you read on your other device.
Get the full title to continue reading from where you left off, or restart the preview.